psychiatryadvisor.com1d
Spravato Approved as Monotherapy for Treatment-Resistant Depression
The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.
Pharm Exec2d
FDA Approves Johnson & Johnson’s Spravato for Treatment-Resistant Depression
CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).
Medindia3d
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...
pharmaphorum4d
J&J builds case for antidepressant Spravato with head-to-head trial
Johnson & Johnson's Spravato therapy for treatment-resistant depression (TRD) hasn't made the impact the company hoped for in the market, and it is looking to new clinical results to accelerate ...
pharmaphorum2d
FDA approves Janssen’s ketamine-based nasal antidepressant
The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...